This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations. The company reported revenue of $10.64 billion and earnings of $1.21 on a per-share ...

Abbott has a diversified business, exciting growth avenues, and a strong dividend program. The company faces potential obstacles, including legal problems and stiff competition. However, that's no ...

I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value of $135 per share due to their strong R&D pipeline and robust financial performance. Abbott's recent results show 7. ...

How many Broadway shows has George Abbott been in? George Abbott has appeared on Broadway in 13 shows. How many West End shows has George Abbott been in? George Abbott has not appeared in the West ...

Texas governor Gregg Abbott has gone on the record in the past stating that the goal of Operation Lone Star, his administration's plan aimed at curbing unlawful migration is "reducing illegal ...

Now, medical device companies, including north suburban-based Abbott Laboratories, are hoping health enthusiasts will embrace a new type of wellness accessory: wearable sensors to track glucose ...

The highly-anticipated crossover between ABC’s “Abbott Elementary” and FX’s “It’s Always Sunny in Philadelphia” just got bigger. While it was already revealed that the “Sunny ...

Beginning November 1, Texas Governor Greg Abbott will require hospitals in the Lone Star State to disclose information about patients who are noncitizens. Abbott plans to report findings gathered ...

Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Wednesday after its financials for Q3 2024 exceeded Wall Street's forecasts, thanks mainly to the strength in its Pharma ...

Abbott’s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20. Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus prior guidance of $4.61-$4.71 ...